Sylvant: payments to doctors
Payments that named Sylvant as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1M
- Providers
- 4,077
- Transactions
- 7,636
- Average per transaction
- $136
The per-transaction average — $136 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,077 providers the average total is $255, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| EUSA Pharma (US) LLC | $546,755 | 52.5% |
| Recordati_rare_diseases_inc. | $494,365 | 47.5% |
| Johnson & Johnson | $33 | 0.0% |
| Janssen Scientific Affairs, LLC | $18 | 0.0% |